| |
著者: Masami Taniguchi, Chihiro Mitsui, Hiroaki Hayashi, Emiko Ono, Keiichi Kajiwara, Haruhisa Mita, Kentaro Watai, Yosuke Kamide, Yuma Fukutomi, Kiyoshi Sekiya, Noritaka Higashi
雑誌名: Allergol Int. 2019 Jul;68(3):289-295. doi: 10.1016/j.alit.2019.05.001. Epub 2019 Jun 21.
Abstract/Text
The characteristics in AERD are severe adult-onset asthma, eosinophilic rhinosinusitis with nasal polyposis, and CysLT overproduction. The cause of AERD have remained unclear, however the decrease in the production of PGE2 caused by the reduction in COX-2 activity is considered to main pathological mechanism of AERD. The mast cell activation and the interaction between platelets and granulocytes are lead to the CysLT overproduction and severe eosinophilic inflammation. The ongoing activation of mast cells is important key pathogenesis in not only stable AERD but exacerbated AERD by aspirin and NSAIDs. In recent years, type 2 inflammation caused by ILC2 activation in patients with AERD have been attracting attention. Omalizumab is effective option for AERD via suppression of mast cell activation and CysLT overproduction. Dupilumab improves sinus symptoms especially in patients with AERD. In near future, anti-platelet drug, CRTH2 antagonist, and anti-TSLP antibody may be useful candidates of therapeutic options in patients with AERD.
Copyright © 2019 Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.
PMID 31235242 Allergol Int. 2019 Jul;68(3):289-295. doi: 10.1016/j.alit.2019.05.001. Epub 2019 Jun 21.
|
